

Dual Research on Drug Efficacy and Toxicity: A Multidisciplinary Integration Perspective

Yihan Liu^{1,*}

¹School of NOIC Academy, 50 Featherstone Ave, Markham, Canada

*Corresponding author:
hhfgyfydytxddxytcuyfguiv@outlook.com

Abstract:

In modern society, drugs serve as the most prevalent approach to treating diseases. Nevertheless, while combating illnesses, drugs may also trigger adverse responses in the human body, encompassing side effects, toxic reactions, allergic reactions, secondary reactions, residual effects, and teratogenic effects. Take rifampicin as an example: excessive administration of this drug can lead to acute or chronic toxic damage to the circulatory, respiratory, and nervous systems, as well as disrupt the functions of the liver, kidneys, bone marrow, and endocrine organs.[1] Consequently, identifying the potential toxicity of drugs and safeguarding medication safety have become a crucial component in the process of drug research and development (R&D) and clinical application. As technologies like multi-omics, systems biology, and artificial intelligence (AI) continue to advance, interdisciplinary research has gradually evolved into a new paradigm for assessing drug efficacy and toxicology. This paper aims to explore the synergistic mechanisms underlying drug efficacy and toxicity across multiple biological levels, including molecular, cellular, organ, and systemic levels.

Keywords: List the; keywords covered; in your paper.

1. Introduction

The study of drug action and toxicity exhibits the characteristic of “two sides of the same coin,” yet traditional research often addresses these two aspects separately. This fragmented approach results in insufficient understanding among most individuals regarding the specific effects of drugs, their therapeutic mechanisms, and associated side effects. In clinical settings, beyond their therapeutic benefits, drugs

also harbor non-negligible toxic reactions, which frequently involve multiple biological levels such as molecules, cells, organs, and systems. At the molecular level, for instance, the activation of drug targets can simultaneously yield therapeutic effects and potential toxicity. At the organ level, drugs may induce abnormal organ function.

Morphine serves as a typical example. In clinical treatment, morphine exerts analgesic and sedative effects by binding to opioid receptors in pain trans-

mission regions such as the spinal cord, medulla oblongata, midbrain, and thalamus, thereby increasing the pain threshold. Additionally, it binds to opioid receptors on neurons in the mesolimbic dopamine system—including the cerebral cortex, hippocampus, nucleus accumbens, and ventral tegmental area—reducing the activity of inhibitory interneurons and enhancing the activity of dopamine (DA) neurons. This process elevates the excitability of relevant reward regions in the brain, leading to a sense of euphoria. However, in some patients or pain-free individuals, administration of a single dose of morphine may instead cause restlessness. Moreover, while producing analgesic effects, morphine often induces symptoms such as drowsiness, confusion, and impaired comprehension. Due to its addictive properties and central nervous system side effects, morphine is classified as a strictly controlled narcotic drug; thus, outside of hospital settings, it is subject to rigorous regulation as a controlled substance.

In the process of drug R&D, inadequate understanding of drug toxicity can increase research costs and consume substantial human resources and time. Therefore, it is essential to conduct toxicological research on drugs during R&D to optimize and improve them, thereby ensuring clinical medication safety [1].

When investigating drug efficacy and toxicity, focusing solely on a single biological level—for example, analyzing the therapeutic effects of drug-receptor binding merely from the perspective of molecular targets—easily overlooks the intracellular metabolism of drugs and their impacts on organs. This narrow focus is detrimental to the comprehensive treatment of patients. In recent years, the development of emerging technologies has provided new tools and perspectives to address this issue. Specifically, advancements in multi-omics, systems biology, and AI have enabled cost reduction, risk mitigation, and increased efficiency in drug R&D. For instance, multi-omics technology integrates genomic, transcriptomic, proteomic, and metabolomic data to comprehensively uncover the molecular mechanisms of toxicant action [2]. It can identify changes in key genes, proteins, and metabolites following toxicant exposure, thereby facilitating the construction of network models for toxic effects. Systems biology aids in data integration, while AI enables rapid data and information mining to support research.

In summary, multidisciplinary integration breaks away from traditional research approaches, enabling dual research on drug efficacy and toxicity. By comprehensively analyzing the advantages and disadvantages of drugs across multiple biological levels, these new technologies provide more scientific and comprehensive theoretical support for drug R&D and clinical application.

2. Synergistic Mechanisms of Drug Ef-

ficacy and Toxicity

2.1 Pathway Overlap at the Molecular and Cellular Levels

2.1.1 Bidirectional Effects of Drug Targets

At the molecular and cellular levels, drug efficacy and toxicity often originate from identical or overlapping pathways—a key reason for the coexistence of therapeutic effects and side effects in clinical practice. Many drugs exert their therapeutic effects by acting on specific targets. Targeted therapy, a treatment strategy focused on specific molecular targets, aims to enhance therapeutic efficacy while minimizing damage to normal cells. The core of targeted therapy lies in identifying and utilizing unique molecular markers of tumor cells, such as growth factor receptors and signal transduction molecules, to achieve precise intervention. With the development of biotechnology and molecular biology, targeted therapy has become a vital direction in cancer treatment, demonstrating significant efficacy in managing various types of cancer. However, targeted therapy also has limitations; for example, cardiotoxicity induced by targeted drugs mainly includes QT interval prolongation, myocardial ischemia/myocardial infarction, left ventricular dysfunction/reduced left ventricular ejection fraction (LVEF), and chronic heart failure [3].

2.1.2 Shared Signaling Pathways

The PI3K-Akt signaling pathway is a critical signal transduction network in cells. It can be activated by various cellular stimuli or toxic damage and plays a pivotal role in regulating basic cellular functions such as transcription, translation, proliferation, growth, and survival. This pathway interacts with multiple others signaling pathways to collectively regulate cell survival, proliferation, migration, metabolism, and additional functions [4].

The NF- κ B pathway and PI3K/Akt pathway both play important roles in physiological and pathological cellular processes, jointly regulating cell survival, proliferation, inflammatory responses, and immune responses. Akt can directly or indirectly activate the IKK complex through other molecules, promoting the phosphorylation and degradation of I κ B. This process releases NF- κ B, allowing it to enter the nucleus and activate the transcription of target genes. Meanwhile, the target genes of NF- κ B include factors that regulate the PI3K/Akt pathway, forming a complex regulatory network involving feedback and positive feedback loops.

2.2 Drug Metabolism and Toxicity Generation

2.2.1 Involvement of Hepatic Drug-Metabolizing Enzymes in Metabolite Transformation and Toxic Inter-

mediate Production

Hepatic drug-metabolizing enzymes, also known as liver metabolic enzymes, are a class of enzymes involved in drug metabolism. The metabolic process of drugs typically consists of two phases:

Phase I Reactions: Primarily mediated by the cytochrome P450 (CYP) enzyme system, these reactions mainly involve oxidation, reduction, and hydrolysis. They chemically modify drug molecules to increase their polarity, laying the groundwork for subsequent metabolic processes. During this phase, some drugs may be converted into toxic intermediates [5].

Phase II Reactions: Mainly catalyzed by various transferases, such as glucuronosyltransferases and glutathione transferases. These enzymes conjugate polar groups (e.g., glucuronic acid, glutathione) to the products of Phase I reactions, further increasing their polarity and water solubility. Ultimately, this facilitates the excretion of drugs and their metabolites from the body.

Although the primary function of hepatic drug-metabolizing enzymes is to convert drugs into more excretable forms, under certain circumstances, intermediates produced during drug metabolism may exhibit toxicity, causing damage to the liver or other organs. For example, some drugs are converted into highly reactive intermediates during Phase I reactions; these intermediates can bind to cellular macromolecules, leading to cell damage or necrosis. Additionally, metabolites of some drugs may trigger immune responses, further exacerbating liver injury.

2.2.2 Genetic Polymorphism and Individual Differences in Toxicity

Genetic polymorphism—particularly that of genes encoding the cytochrome P450 (CYP450) enzyme family—is a key factor contributing to individual differences in drug-induced toxic reactions. CYP450 enzymes are involved in the metabolism of most drugs in the human body. Different genotypes result in variations in enzyme activity and expression levels, which in turn affect the rate of drug metabolism in the body, the production of metabolites, and ultimately, the efficacy and toxicity of drugs. Genetic polymorphism influences drug toxicity through three main pathways: drug metabolism rate, metabolite toxicity, and individual sensitivity [6].

3. Integrated Research Technologies and Methods

3.1 Multi-Omics Integration

Multi-omics integration technology synchronously analyzes the dynamic correlations between gene expression (transcriptomics), metabolite changes (metabolomics),

and protein levels (proteomics) in organisms following drug exposure. By constructing a comprehensive regulatory network of “gene-protein-metabolite,” this technology enables the simultaneous capture of both therapeutic effect signals and potential toxicity signals of drugs.

Historically, cardiotoxicity associated with anti-tumor drug therapy was primarily caused by anthracyclines and radiotherapy. In recent years, however, increasing reports have focused on tyrosine kinase inhibitors (TKIs)—a class of molecular targeted drugs. Mounting evidence indicates that TKIs carry the risk of inducing cardiotoxicity: some patients develop symptomatic congestive heart failure, while others experience asymptomatic left ventricular dysfunction.

Trastuzumab (Herceptin), a monoclonal antibody targeting the human epidermal growth factor receptor, was the first molecular targeted drug found to exhibit cardiotoxicity. Its most prominent cardiotoxic effect is asymptomatic reduction in LVEF, with an overall incidence ranging from 4.2% to 13.1% [7]. Clinical studies on imatinib have also reported reduced LVEF and congestive heart failure in patients; Phase II clinical trial results showed that 1% of patients taking imatinib experienced adverse events related to heart failure and cardiac dysfunction [8]. Additionally, currently used TKIs such as dasatinib, sunitinib, sorafenib, and bevacizumab all pose a risk of cardiotoxicity. However, certain other types of TKIs do not induce cardiotoxicity, indicating that this is not a universal effect of all TKIs. Thus, it is necessary to conduct specific toxicological analyses for each individual drug.

Currently, two main mechanisms are proposed to explain TKI-induced cardiotoxicity: first, TKIs cause oxidative stress-mediated mitochondrial damage in cardiomyocytes; second, TKIs inhibit the translation of myocardial proteins, thereby severely compromising cardiomyocyte survival. However, protective strategies based on these two mechanisms have not achieved the expected results, suggesting that the mechanisms underlying TKI-induced cardiotoxicity are more complex and that additional key molecular biological mechanisms remain to be discovered.

The occurrence of adverse reactions limits the clinical application of molecular targeted anti-tumor drugs, thereby reducing their anti-tumor efficacy. Therefore, in-depth research into the toxic mechanisms of these drugs, as well as the search for appropriate solutions and effective protective measures, has become a critical focus in current anti-tumor drug toxicology research. Furthermore, the observation that only some drugs within the same class of molecular targeted drugs induce toxic reactions suggests that the toxicity of molecular targeted anti-tumor drugs may not be caused by target proteins. Hence, specific toxicological mechanism studies for different drugs are

required.

3.2 Bioinformatics and Systems Biology Modeling

Bioinformatics tools enable the mining of correlation patterns between drug efficacy and toxicity from large-scale biological data, while systems biology modeling can transform these patterns into visual network models, facilitating mechanism analysis and risk prediction.

In the application of network pharmacology, researchers studied an anti-hypertensive drug by first screening 128 potential action targets of the drug through databases. They then integrated these targets with 342 key targets associated with hypertension to construct a “drug-target-disease” interaction network. Analysis of this network revealed that, in addition to exerting its hypotensive effect by acting on angiotensin-converting enzyme (ACE), the drug could also bind to β 2-adrenergic receptors (ADRB2) in cardiomyocytes. This association had been overlooked in traditional research; however, subsequent experiments confirmed that this binding could induce abnormal myocardial contractile function, explaining the toxic mechanism underlying palpitations observed in some patients following clinical administration [9].

In addition, a “target-side effect network prediction platform” developed based on large-scale clinical medication data can automatically match the probability of side effects of similar drugs in historical data by inputting the molecular structure and action targets of a drug. Before a new type of hypoglycemic drug entered clinical trials, this platform successfully predicted the risk of “potential renal tubular damage.” Subsequent animal experiments verified this prediction, providing a basis for adjusting clinical trial protocols [10].

3.3 Organoids and Human-Derived Models

Owing to their high similarity to human physiological structures and functions, organoids and human-derived models effectively address the species differences inherent in traditional animal experiments, providing a new tool for the accurate in vitro evaluation of drug efficacy and toxicity.

Compared with animal models, human liver organoids not only retain the typical morphology of hepatocytes (e.g., liver lobule structure) but also possess a complete hepatic drug-metabolizing enzyme system (such as various subtypes of the CYP450 family). This allows them to more accurately simulate the metabolic process of drugs in the human liver during hepatotoxicity screening. In a hepatotoxicity assessment study of an antibiotic, traditional mouse experiments failed to detect obvious liver damage. In contrast, in human liver organoids, intermediates produced by drug metabolism significantly induced

hepatocyte apoptosis, and the apoptosis rate exhibited a dose-dependent relationship with drug concentration. This result was highly consistent with the subsequent clinical observation of elevated liver enzymes in some patients after drug administration [11].

Furthermore, human intestinal organoids can be used to evaluate the intestinal absorption efficiency and intestinal toxicity of drugs. In the case of an oral anti-inflammatory drug, human intestinal organoid models revealed that the drug disrupted the tight junctions of the intestinal epithelium, leading to impaired intestinal barrier function. The discovery of this toxic mechanism prompted the transformation of the drug’s dosage form from conventional tablets to enteric-coated preparations, reducing the occurrence of intestinal irritation side effects [12].

3.4 Application of AI and Machine Learning in Toxicological Prediction

By learning from large volumes of historical experimental data and clinical data, AI and machine learning technologies can construct efficient drug-toxicity correlation models, enabling rapid prediction and screening of toxicity risks.

In terms of model construction, researchers collected data on the molecular structure, action targets, in vitro experimental results, and clinical side effect records of 1,500 known drugs. They then used the random forest algorithm to train a “drug-toxicity correlation model.” When applied to predict the toxicity of 50 new candidate drugs, this model achieved an accuracy rate of 82%. For a specific anti-tumor candidate drug, the model predicted a risk of “potential bone marrow suppression.” Subsequent in vitro experiments on bone marrow hematopoietic stem cells confirmed that the drug could inhibit the proliferation and differentiation of hematopoietic stem cells, which was consistent with the prediction [13].

In the risk assessment of side effects based on big data, natural language processing technology was used to mine 2 million global drug adverse reaction reports, leading to the construction of a “drug-adverse reaction-population characteristic” correlation database. Analysis of this database for a specific antidepressant revealed that the risk of hemorrhagic stroke in the population of “elderly women with concurrent use of non-steroidal anti-inflammatory drugs” was 3.7 times higher than that in the general population. This finding provided data support for the stratified management of clinical medication populations, reducing medication risks for high-risk groups [14].

4. Summary

The “two sides of the same coin” characteristic of drug efficacy and toxicity means that single-discipline research

cannot achieve a comprehensive assessment. Multidisciplinary integration, however, provides a key pathway to address this challenge. This study systematically organized the synergistic mechanisms of drug efficacy and toxicity, identifying that pathway overlap at the molecular and cellular levels (e.g., the PI3K/AKT pathway) and individual differences in drug metabolism (e.g., CYP450 genetic polymorphism) are the core biological foundations underlying the correlation between efficacy and toxicity. Simultaneously, this study summarized the application scenarios of integrated technologies such as multi-omics integration, systems biology modeling, organoid technology, and AI prediction. It confirmed that these technologies can simultaneously advance the research on drug efficacy mechanisms and the management of toxicity risks across multiple dimensions, including data mining, mechanism analysis, in vitro evaluation, and risk prediction. Multidisciplinary integration not only uncovers “efficacy-toxicity” correlation mechanisms overlooked in traditional research (e.g., the effect of anti-hypertensive drugs on myocardial ADRB2) but also improves the efficiency and accuracy of evaluation through in vitro models and AI tools, thereby reducing clinical medication risks.

Future research should further promote the collaborative application of multiple technologies—for example, combining multi-omics data with AI models to construct a closed-loop research system of “real-time prediction-experimental verification-model optimization.” At the same time, it is necessary to accelerate the standardization of organoid models to improve their reproducibility and comparability across different laboratories. Additionally, efforts should be made to promote the clinical translation of interdisciplinary integration research results, establish an “integrated efficacy-toxicity evaluation standard,” and provide more systematic scientific basis for early screening in drug R&D, clinical trial design, and clinical medication guidance. Ultimately, this will achieve the goals of drug safety and precision medicine, providing support for improving clinical treatment outcomes and reducing the incidence of adverse drug reactions.

References

- [1] World Health Organization. (2017). *Guidelines for the safe use of rifampicin in the treatment of tuberculosis*. Geneva: WHO Press.
- [2] Zhang, Y., Li, J., Wang, H., et al. (2023). Construction of target-toxicity mapping for antitumor drugs via multi-omics integration to guide drug structure optimization. *Journal of Pharmaceutical Analysis*, 13(4), 589–602.
- [3] Sacco, E., Minotti, G., Menna, P., et al. (2015). Cardiotoxicity of targeted anticancer drugs: The need for a multidisciplinary approach. *Annals of Oncology*, 26(Suppl 5), v204–v212.
- [4] Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: Navigating the network. *Cell*, 129(7), 1261–1274.
- [5] Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics*, 138(1), 103–141.
- [6] Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics Journal*, 5(1), 6–13.
- [7] Swain, S. M., Whaley, F. S., & Ewer, M. S. (2000). Cardiotoxicity of the Herceptin (trastuzumab) in a patient with metastatic breast cancer. *New England Journal of Medicine*, 342(19), 1401–1402.
- [8] Chung, C. H., Lipshultz, S. E., Lipsitz, S. R., et al. (2005). Cardiotoxicity associated with imatinib mesylate therapy. *Journal of Clinical Oncology*, 23(10), 2275–2280.
- [9] Chen, S., Zhao, L., Liu, X., et al. (2022). Network pharmacology-based analysis of the toxic mechanism of an antihypertensive drug targeting ADRB2 in cardiomyocytes. *British Journal of Pharmacology*, 179(15), 3872–3885.
- [10] Wang, Q., Zhang, H., Chen, J., et al. (2024). Development and validation of a target-side effect network prediction platform for early risk assessment of new hypoglycemic drugs. *Pharmaceutical Research*, 41(2), 678–691.
- [11] Li, M., Hua, Y., Zhang, S., et al. (2023). Human liver organoids reveal hepatotoxicity of an antibiotic that is undetected in mouse models. *Hepatology*, 78(3), 1124–1137.
- [12] Zhao, Y., Wu, J., Li, D., et al. (2022). Intestinal organoid model identifies intestinal barrier damage induced by an oral anti-inflammatory drug and guides dosage form optimization. *Journal of Controlled Release*, 345, 89–101.
- [13] Liu, C., Yang, H., Wang, Z., et al. (2024). A random forest-based drug-toxicity correlation model for predicting bone marrow suppression of antitumor candidates. *Computational Biology and Chemistry*, 103, 107789.
- [14] Huang, L., Zhang, J., Chen, G., et al. (2023). Natural language processing of global adverse drug reaction reports to identify high-risk populations for hemorrhagic stroke induced by an antidepressant. *Pharmacoepidemiology and Drug Safety*, 32(5), 612–621.